Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Coherus BioSciences Announces Clinical Collaboration With STORM Therapeutics To Evaluate STC-15, METTL3 Inhibitor, In Combination With LOQTORZI, Next-Gen PD-1 Inhibitor, In Phase 1b/2 Study For NSCLC, HNSCC, Melanoma And Endometrial Cancer Treatment

Author: Benzinga Newsdesk | May 27, 2025 07:36am

Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS), today announced a clinical collaboration with STORM Therapeutics, Ltd. ("STORM") to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor, in a Phase 1b/2 study for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma and endometrial cancer.

Posted In: CHRS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist